NCIC CLINICAL TRIALS GROUP – GI DISEASE SITE COMMITTEE

COLON

DISEASE ORIENTED GROUP

AGENDA

OPEN SESSION

VENUE: ROSSETTI ROOM, EATON CHELSEA HOTEL, TORONTO

DATE SATURDAY, MAY 2nd, 2015

TIME: 8:30 – 10:15

CHAIRS: DR. DEREK JONKER, DR. SHARLENE GILL

8:30 WELCOME AND INTRODUCTION  DR. D. JONKER / DR. S. GILL

8:30 CLOSED TRIALS AWAITING ANALYSIS

IND 210: A RANDOMIZED PHASE II STUDY OF FOLFOX/BEVACIZUMAB +/- REOLYSIN IN METASTATIC COLORECTAL CANCER  DR. D. JONKER ON BEHALF OF DR. P. TANG

CO.23: A PHASE III RANDOMIZED STUDY OF BBI608 AND BEST SUPPORTIVE CARE VERSUS PLACEBO AND BEST SUPPORTIVE CARE IN PATIENTS WITH PRETREATED ADVANCED COLORECTAL CARCINOMA  DR. D. JONKER

8:35 APPROVED/ACTIVE TRIALS FOR UPDATE/DISCUSSION

IND 208: A PHASE I TRIAL OF PANITUMUMAB + BKM120, AN ORAL PI3K INHIBITOR IN COLORECTAL CANCER  DR. D. JONKER ON BEHALF OF DR. R. GOODWIN

IND 214: A PHASE I/II TRIAL OF MG1MA3 WITH AND WITHOUT ADVAC/MA3 IN PATIENTS WITH ADVANCED/METASTATIC COLORECTAL OR NON SMALL CELL LUNG CANCER  DR. D. JONKER

CO.21: A PHASE III STUDY OF THE IMPACT OF A PHYSICAL ACTIVITY PROGRAM ON DISEASE-FREE SURVIVAL IN PATIENTS WITH EARLY STAGE COLON CANCER: A RANDOMIZED CONTROLLED TRIAL (CHALLENGE)  DR. D. JONKER ON BEHALF OF DR. K. COURNEYA & DR. C. BOOTH

CRC.6: (CALGB 80702): A PHASE III TRIAL OF 6 VERSUS 12 TREATMENTS OF ADJUVANT FOLFOX PLUS CELECOXIB OR PLACEBO FOR PATIENTS WITH RESECTED STAGE III COLON CANCER  DR. D. JONKER ON BEHALF OF DR. F. COUTURE

CO.25 (FOCUS 4): MOLECULARLY STRATIFIED RCT PROGRAMME FOR SELECTION OF THERAPY IN METASTATIC CRC POST INDUCTION 1ST LINE TREATMENT  DR. R. GOODWIN
NCIC CLINICAL TRIALS GROUP – GI DISEASE SITE COMMITTEE

COLON
DISEASE ORIENTED GROUP
AGENDA
OPEN SESSION
VENUE: ROSSETTI ROOM, EATON CHELSEA HOTEL, TORONTO
DATE SATURDAY, MAY 2nd, 2015
TIME: 8:30 – 10:15
CHAIRS: DR. DEREK JONKER, DR. SHARLENE GILL

8:55 CONCEPTS IN DEVELOPMENT/TRIAL PROPOSALS

PERIOPERATIVE LOW MOLECULAR WEIGHT HEPARIN TO IMPROVE SURVIVAL FOLLOWING RESECTION OF COLORECTAL CANCER

DR. R. AUER

9:05 GUEST PRESENTATION - ASTRAZENECA IMMUNOTHERAPY PIPELINE

DR. A. SHALABI

CONCEPTS FOR DEVELOPMENT

DR. D. JONKER / DR. S. GILL

- MEDI4736 + TREMELIMUMAB IN ADVANCED/METASTATIC REFRACTORY CRC
- FIRST LINE FOLIRI +/- MEDI4736 IN CRC

10:00 ADJUVANT HIGH-RISK PROPOSALS – ECOG/ACRIN & IROCAS

DR. S. GILL

CLOSING REMARKS